![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated
interferon alfa-2a
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
![0521181](../images%20/052118/052118-7/0521181.gif)
![0521182](../images%20/052118/052118-7/0521182.gif)
![0521183](../images%20/052118/052118-7/0521183.gif)
![0521184](../images%20/052118/052118-7/0521184.gif)
![0521185](../images%20/052118/052118-7/0521185.gif)
![0521186](../images%20/052118/052118-7/0521186.gif)
![0521187](../images%20/052118/052118-7/0521187.gif)
![0521188](../images%20/052118/052118-7/0521188.gif)
![0521189](../images%20/052118/052118-7/0521189.gif)
![05211810](../images%20/052118/052118-7/05211810.gif)
![05211811](../images%20/052118/052118-7/05211811.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|